Galen

What Galen does

Galen Limited is a privately owned pharmaceutical sales and marketing company founded in 1968 and headquartered in Craigavon, Northern Ireland, operating as the founding member of the Almac Group (wholly owned by the McClay Foundation). The company commercializes 75+ products across multiple therapy areas — gastroenterology (Laxido), urology, female health (Cariban for nausea and vomiting in pregnancy), pain management and emergency medicine (Penthrox, GelX Oral Spray), respiratory diagnostics (Provocholine for bronchial challenge testing), dermatology and topical anaesthesia (Synera lidocaine/tetracaine patch), and a medical nutrition portfolio addressing metabolic disorders including Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Tyrosinaemia (TYR), and Urea Cycle Disorders (UCD). Products are sourced through a mix of in-licensing (e.g., Italfarmaco, Methapharm, Istituto Gentili, Salvat, Penlan Healthcare, Sunstar Suisse), out-licensing (Almeda Pharmaceuticals, Bora Health), and outright acquisitions (Synera from ZARS Pharma/Nuvo Research in 2013; POA Pharma Scandinavia AB in 2020).

Galen's revenue model rests on pharmaceutical product sales through direct commercial operations, licensing royalties, and product acquisition agreements. It generates revenue by selling or distributing licensed and acquired products across the UK, Republic of Ireland, the Nordics, continental Europe, and the United States, with pricing set by licensing terms, government reimbursement schemes (e.g., Ireland's Drugs Payment Scheme), and institutional procurement. Distribution is handled through wholly-owned subsidiaries (POA Pharma Scandinavia AB, POA Pharma GmbH, Galen Pharma Ireland Limited, Galen US Inc.) and channel partners such as Nexus Patient Services for US medical nutrition. The company does not develop proprietary technology platforms; its value is operational — sales, marketing, market access, regulatory affairs, and pharmacovigilance capabilities — applied to niche and rare-disease assets. Management is led by Dr Dennise Broderick (Managing Director and President since 2019), with Simon Lawrence as VP of Marketing and Medical Nutrition with 35+ years of tenure, and approximately 150 staff at the Craigavon site alongside broader teams across the POA Pharma subsidiaries and US operations.

Name

Galen

Legal name

Galen Limited

Website

https://galen-pharma.com

Company type

Private

Founded year

1968

Operating status

Operating

Headcount range

11–50 employees

Short description

Galen Limited is a privately owned, Northern Ireland-headquartered pharmaceutical sales and marketing company (founded 1968, part of the McClay Foundation-owned Almac Group) that commercializes 75+ prescription and medical nutrition products across the UK, Ireland, Nordics, Europe, and USA via in-licensing, acquisitions, and direct field sales.

Ownership category

akta.pro rank

Product category

Pharmaceutical Commercialization Services

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industry

Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience) (CRAOAHAG)

Keywords

• Pharmaceutical sales and marketing
• Pharmaceutical commercialization services
• Medical nutrition products
• Specialty pharmaceuticals distribution
• Pharmaceutical in-licensing and acquisitions

Headquarters

HQ city

Souderton

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Supply Chain, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Galen generates revenue through the sale and marketing of pharmaceutical products across multiple therapy areas including gastroenterology, urology, female health, pain management, mental health, medical nutrition, and dermatology. Products are distributed across UK, Ireland, Nordics, Europe, and USA through direct commercial operations.
2. Licensing and Distribution Agreements: Galen enters into exclusive licensing agreements with pharmaceutical companies to distribute their products in specific territories. Examples include Cariban in Ireland (Italfarmaco), Provocholine in UK (Methapharm), and various in-licensing/out-licensing arrangements.
3. Product Acquisitions: Galen acquires rights to market and sell pharmaceutical products through product acquisition agreements, such as Synera in the US. These acquisitions involve upfront payments and ongoing royalties based on sales performance.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Galen Limited is a privately owned pharmaceutical sales and marketing company that commercializes and distributes a portfolio of 75+ prescription medicines and medical nutrition products across gastroenterology, female health, pain management, mental health, medical nutrition, and dermatology. The company partners with pharmaceutical manufacturers through in-licensing, out-licensing, and acquisition arrangements to bring products to market in the UK, Ireland, Nordics, Europe, and USA, offering comprehensive services including sales, marketing, launch excellence, market access, regulatory affairs, pharmacovigilance, and medical affairs.

Product overview

Galen is a privately owned pharmaceutical sales and marketing company established in 1968, headquartered in Craigavon, Northern Ireland, with commercial operations in the UK, Europe, and the USA. The company operates as part of the Almac Group and offers a diverse portfolio of over 75 products across multiple therapeutic areas. The core offering includes prescription medicines (Cariban for nausea and vomiting in pregnancy, Provocholine for asthma diagnosis, Synera for topical anaesthesia) and medical nutrition products (PKU EASY Microtabs Plus, TYR EASY Tablets, and broader portfolio for metabolic disorders like PKU, MSUD, TYR, and UCD). Galen also markets acute care products including Penthrox for emergency medicine and GelX for supportive cancer care. The company operates through direct sales teams and international partnerships, distributing products across 25 global locations.

Differentiator

Problem solved

Functional benefit

Brands

• Galen Medical Nutrition: Medical nutrition products for metabolic disorders including PKU, MSUD, TYR, and UCD

Products and services

• PKU EASY Microtabs Plus A phenylalanine-free protein substitute enriched with vitamins, minerals, and essential and non-essential amino acids for individuals with Phenylketonuria (PKU). Designed to replace the requirement for a separate vitamin and minerals supplement.
• TYR EASY Tablets First solid-dose protein substitute option for tyrosinaemia (TYR), supporting dietary management for patients over the age of 8.
• Cariban (doxylamine/pyridoxine) Medication for the treatment of nausea and vomiting in pregnancy (NVP). Available in Ireland through the Drugs Payment Scheme or Medical Card.
• Provocholine (methacholine chloride) 100mg powder for nebuliser solution used to detect bronchial airway hyperreactivity, assisting in the diagnosis of asthma in patients aged 17 and over.
• Synera (lidocaine/tetracaine) Topical patch combining lidocaine and tetracaine with heat technology (CHADD) for local dermal analgesia during superficial venous access and dermatological procedures. Indicated for use on intact skin in patients 3 years or older.
• Medical Nutrition Portfolio Innovative medical foods for dietary management of metabolic disorders including Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Tyrosinemia (TYR), and Urea Cycle Disorders (UCD).
• Laxido Product for gastrointestinal treatment that became central to Galen's success.
• Penthrox Inhaled analgesic for accident and emergency departments, providing rapid pain relief for common injuries.
• GelX Oral Spray Oral spray product that can improve quality of life for cancer patients.

Quantifiable outcome

• Fully reimbursed access to NVP treatment in Ireland
• +1 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

15 partnerships are on record, tiered major, minor and core.

• Istituto GentilimajorChannel Partner/ Reseller/ Distributor · 16 April 2026New licensing partnership announced April 2026 where Galen's subsidiary POA Pharma Scandinavia AB assumes exclusive distribution responsibilities across Denmark, Finland, and Norway for a medication used in paediatric care. The partnership strengthens Galen's long-term strategy in Northern Europe and reinforces commitment to improving access to essential therapies.
• SalvatminorChannel Partner/ Reseller/ Distributor · 13 February 2026New exclusive licensing partnership for expansion of Nordic ENT portfolio. POA Pharma Scandinavia AB, part of Galen group, entered partnership to expand ENT (Ear, Nose, Throat) product offerings in Nordic region.
• Ulster UniversitymajorStrategic or Co-development Partner · 22 October 2024Three-year partnership with Ulster University to support BSc Hons Paramedic Science programme. Galen sponsors the Paramedic Science Award for Extraordinary Peer Support, Enhancing the Potential of Others, recognizing students who demonstrate exceptional peer support and help fellow students reach their full potential.
• ItalfarmacocoreChannel Partner/ Reseller/ Distributor · 30 July 2024Exclusive licensing agreement with Italfarmaco for Cariban (doxylamine/pyridoxine) in Ireland for treatment of nausea and vomiting in pregnancy. This brought the first fully reimbursed supply of the product to Ireland with €1 million government allocation in 2023. Galen serves as exclusive distributor enabling easier patient access through GP prescriptions.
• Almeda Pharmaceuticals AGmajorChannel Partner/ Reseller/ Distributor · 25 January 2024Exclusive licensing deal granting Almeda Pharma rights to license Galen's PKU EASY Microtabs Plus across Ukraine, Moldova, Georgia, Armenia, Azerbaijan, and Kazakhstan. This partnership advances Galen's global expansion strategy to make products available to wider populations and enhance patient outcomes.
• Penlan Healthcare LimitedminorChannel Partner/ Reseller/ Distributor · 19 September 2023POA Pharma secured exclusive in-licensing agreement with Penlan Healthcare Limited for Rapilose Oral Glucose Solution (OGS) for entry into German market.
• Methapharm Specialty PharmaceuticalsmajorChannel Partner/ Reseller/ Distributor · 11 April 2022Galen acquired rights to exclusively distribute and commercialize Provocholine (methacholine chloride) in the United Kingdom. Provocholine is used for bronchial airway hyperreactivity detection to assist in asthma diagnosis, addressing approximately 5.4 million asthma patients in UK.
• Global Emergency Care Skills (GECS)minorGTM or Marketing Partner · 1 January 2022Galen has sponsored GECS non-profit organization for two years, providing scrubs for voluntary trainers who deliver trauma skills training to doctors, nurses and clinical officers in African hospitals. GECS has trained over 600 healthcare staff across Kenya, Zambia, Malawi, Ghana, and Tanzania since 2009.
• Nexus Patient ServicescoreChannel Partner/ Reseller/ Distributor · 15 October 2021Agreement making Nexus Patient Services the sole distributor for Galen Medical Nutrition products in the United States. Nexus provides continued access to high quality medical food products with exceptional customer service, including benefit investigations, prescription dispensing, copay card solutions, and direct-to-patient medication delivery programs.
• POA Pharma Scandinavia ABcoreStrategic or Co-development Partner · 8 January 2020Galen acquired POA Pharma Scandinavia AB for a multi-million pound sum in January 2020, following an initial distribution agreement in 2016. POA was headquartered in Sweden with operations across Nordics and North America, representing 14 producers from 11 countries with strong medical nutrition portfolio. The acquisition provided Galen immediate foothold in Nordic region and served as springboard for European expansion including Germany, Austria, and Netherlands.
• College of ParamedicsmajorStrategic or Co-development Partner · 1 January 2019Partnership with College of Paramedics for the Dr John Hinds Scholarship Award, now in its seventh year (2026). The scholarship provides fully funded place on ATACC course and case study publication for pre-hospital responders across Ireland. Supports emergency medicine professionals and honors Dr John Hinds' legacy.
• POA Pharma GmbHcoreChannel Partner/ Reseller/ DistributorGerman subsidiary established in 2023 as POA Pharma GmbH for distribution, marketing, and commercialization of proprietary, generic, and rare disease medication in Germany. Part of Galen's strategic expansion into Europe's largest pharmaceutical market.
• Bora Health IncmajorChannel Partner/ Reseller/ DistributorExclusive licensing agreement with Taiwan-based Bora Health Inc for Microtabs Plus. Partnership grants Bora Health rights to license and distribute PKU EASY Microtabs Plus, expanding Galen's global reach in metabolic nutrition products.
• Sunstar Suisse S.A.minorChannel Partner/ Reseller/ DistributorPartnership with Sunstar Suisse S.A. to exclusively distribute and commercialize GelX Oral Spray in the United Kingdom and Ireland.
• ATACC GroupmajorStrategic or Co-development PartnerPartnership with ATACC Group for the Advanced Trauma and Critical Care course that scholarship winners attend. ATACC provides internationally recognized trauma training in the UK.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Almirall: Spanish specialty pharma focused on dermatology and specialty therapeutics with European commercial operations; comparable mid-cap European specialty pharma commercializer.
• Alliance Pharmaceuticals: UK-based specialty pharma that licenses, acquires and commercializes niche prescription products across multiple therapy areas including dermatology and women's health; closely comparable mid-sized UK specialty commercializer.
• Amneal Pharmaceuticals: US-based specialty and generic pharma that acquires, licenses and distributes pharmaceutical products including specialty therapeutics; comparable in its licensing-driven specialty pharma model.
• Chiesi Farmaceutici: Privately owned Italian specialty pharma with a European focus on rare diseases, medical nutrition and specialty therapeutics; closely comparable in foundation/private ownership model and niche therapy focus.
• Norgine: European specialty pharma that develops, licenses and commercializes prescription medicines across gastroenterology and other therapeutic areas; highly comparable business model of licensing-led commercialization in European markets.
• Consilient Health: Privately owned UK and Ireland specialty pharma company of comparable size focused on licensing, marketing and distributing prescription medicines across multiple therapy areas; competes head-to-head with Galen in similar geographies and channels.
• Recordati: Italian specialty pharma with established rare disease and European commercial franchise; comparable in its European geographic focus and specialty/rare disease product orientation, though at larger scale.

Broad incumbents

• Stada Arzneimittel: European generics and specialty pharma distributor with broad portfolio across multiple therapy areas and geographies; larger incumbent operating overlapping European channels.
• Aspen Pharmacare: South African-headquartered global specialty pharma with European and emerging market commercial operations including branded specialty therapeutics; comparable in its specialty commercialization and geographic diversification model.
• Ipsen: French specialty pharma with European and US presence focused on specialty care including gastroenterology and rare diseases; broader incumbent where Galen's MD Dr Dennise Broderick previously served as Country Manager in Ireland.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/AlmacGroup
• LinkedInlinkedin.com/company/galen-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galen